FF-10502 is a pyrimidine nucleoside antimetabolite and a structural analog of Gemcitabine. This compound effectively inhibits DNA polymerase α and β, demonstrating potent anticancer activity by targeting dormant cells.

FF-10502, at concentrations ranging from 0.1 nM to 10 μM and administered over a 72-hour period, demonstrated growth inhibition in various human pancreatic cancer cell lines. Specifically, the IC50 values were determined to be 59.9 nM for BxPC-3, 39.6 nM for SUIT-2, 68.2 nM for Capan-1, and 331.4 nM for MIA PaCa-2 cells, respectively[1]. This efficacy was observed in a Cell Viability Assay, signifying FF-10502's potential in inhibiting pancreatic cancer cell proliferation.

FF-10502, administered intravenously at doses ranging from 120 to 480 mg/kg once weekly for four weeks, exhibited a dose-dependent antitumor effect in a mouse xenograft model. This model involved the subcutaneous implantation of the human pancreatic cancer cell line Capan-1 into five-week-old female nude mice (BALB/c-nu/nu). The study revealed that FF-10502 significantly suppressed tumor growth, with efficacy increasing with the dosage.